Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Mridula A. George, Sadaf Qureshi, Coral Omene, Deborah L. Toppmeyer, Shridar Ganesan

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Targeted therapies such as Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors have improved the prognosis of metastatic hormone receptor (HR) positive breast cancer by combating the resistance seen with traditional endocrine therapy. The three approved agents currently in the market are palbociclib, ribociclib and abemaciclib. Besides the overall similarities associated with CDK4/6 inhibition, there are differences between the three approved agents that may explain the differences noted in unique clinical scenarios- monotherapy, patients with brain metastases or use in the adjuvant setting. This review article will explore the preclinical and pharmacological differences between the three agents and help understand the benefits seen with these agents in certain subgroups of patients with metastatic HR positive breast cancer.

Original languageEnglish (US)
Article number693104
JournalFrontiers in Oncology
StatePublished - Jul 12 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • CDK4/6 cell cycle inhibitors
  • CDK4/6 inhibitors in breast cancer
  • abemaciclib
  • hormone receptor (HR)
  • metastatic breast cancer
  • palbociblib
  • ribociclib


Dive into the research topics of 'Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer'. Together they form a unique fingerprint.

Cite this